How to buy Lyell Immunopharma IncCommon Stock stock

Lyell Immunopharma, Inc. Common Stock is a biotechnology business based in the US. Lyell Immunopharma IncCommon Stock shares (LYEL) are listed on the NASDAQ and all prices are listed in US Dollars. Lyell Immunopharma IncCommon Stock employs 188 staff and has a trailing 12-month revenue of around 0.00.

Lyell Immunopharma IncCommon Stock stock price (NASDAQ: LYEL)

Use our graph to track the performance of LYEL stocks over time.

Lyell Immunopharma IncCommon Stock shares at a glance

• Key figures

Information last updated 2021-07-28.

52-week range	$13.11 - $18.90
50-day moving average	$16.00
200-day moving average	$16.00
Wall St. target price	N/A
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Lyell Immunopharma IncCommon Stock shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Lyell Immunopharma IncCommon Stock stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Lyell Immunopharma, Inc. Common Stock by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lyell Immunopharma IncCommon Stock financials

Revenue TTM	$8.9 million
Gross profit TTM	$7.8 million
Return on assets TTM	0%
Return on equity TTM	0%
Profit margin	0%
Book value	N/A
Market capitalisation	$3.3 billion

TTM: trailing 12 months

Shorting Lyell Immunopharma IncCommon Stock shares

There are currently 2.1 million Lyell Immunopharma IncCommon Stock shares held short by investors – that's known as Lyell Immunopharma IncCommon Stock's "short interest". This figure is 57.5% up from 1.3 million last month.

There are a few different ways that this level of interest in shorting Lyell Immunopharma IncCommon Stock shares can be evaluated.

Lyell Immunopharma IncCommon Stock's "short interest ratio" (SIR)

Lyell Immunopharma IncCommon Stock's "short interest ratio" (SIR) is the quantity of Lyell Immunopharma IncCommon Stock shares currently shorted divided by the average quantity of Lyell Immunopharma IncCommon Stock shares traded daily (recently around 777960.6741573). Lyell Immunopharma IncCommon Stock's SIR currently stands at 2.67. In other words for every 100,000 Lyell Immunopharma IncCommon Stock shares traded daily on the market, roughly 2670 shares are currently held short.

To gain some more context, you can compare Lyell Immunopharma IncCommon Stock's short interest ratio against those of similar companies.

• Agios Pharmaceuticals (AGIO.US): 5.33
• Athenex (ATNX.US): 5.98
• Clovis Oncology (CLVS.US): 4.72

However Lyell Immunopharma IncCommon Stock's short interest can also be evaluated against the total number of Lyell Immunopharma IncCommon Stock shares, or, against the total number of tradable Lyell Immunopharma IncCommon Stock shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lyell Immunopharma IncCommon Stock's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Lyell Immunopharma IncCommon Stock shares in existence, roughly 10 shares are currently held short) or 0.2287% of the tradable shares (for every 100,000 tradable Lyell Immunopharma IncCommon Stock shares, roughly 229 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lyell Immunopharma IncCommon Stock.

Find out more about how you can short Lyell Immunopharma IncCommon Stock stock.

Lyell Immunopharma IncCommon Stock share dividends

We're not expecting Lyell Immunopharma IncCommon Stock to pay a dividend over the next 12 months.

Lyell Immunopharma IncCommon Stock overview

Lyell Immunopharma, Inc. , a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. .

Frequently asked questions

What percentage of Lyell Immunopharma IncCommon Stock is owned by insiders or institutions?
Currently 16.006% of Lyell Immunopharma IncCommon Stock shares are held by insiders and 1.273% by institutions. How many people work for Lyell Immunopharma IncCommon Stock?
Latest data suggests 188 work at Lyell Immunopharma IncCommon Stock. When does the fiscal year end for Lyell Immunopharma IncCommon Stock?
Lyell Immunopharma IncCommon Stock's fiscal year ends in December. Where is Lyell Immunopharma IncCommon Stock based?
Lyell Immunopharma IncCommon Stock's address is: 400 East Jamie Court, South San Francisco, CA, United States, 94080